Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy

BACKGROUND: Alterations in the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway are frequent in urothelial bladder cancer (BLCA) and thus provide a potential target for novel therapeutic strategies. We investigated the efficacy of the AKT inhibitor MK-22...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathe, A, Guerth, F, Cronauer, M V, Heck, M M, Thalgott, M, Gschwend, J E, Retz, M, Nawroth, R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260039/
https://www.ncbi.nlm.nih.gov/pubmed/25349966
http://dx.doi.org/10.1038/bjc.2014.534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260039/
https://www.ncbi.nlm.nih.gov/pubmed/25349966
http://dx.doi.org/10.1038/bjc.2014.534

Ejemplares similares